AbstractThe objective of the research was to study the features of impaired fibrinolytic and proteolytic activity of blood plasma in patients with osteoarthritis (OA), depending on the age levels of comorbidity.Material and methods. The age features of comorbid processes prevalence in 120 patients with OA were clinically studied, fibrinolytic and proteolytic activity of blood, levels of fibrinogen and C-reactive protein were also studied using biochemical methods.Results. Comorbidity in patients with OA at the age under 50 was established low. The level of comorbidity increases to at the age of 51-60, after 60 years the phenomenon of comorbidity is more significant by frequency and severity. The diseases of the cardiovascular system dominated, including metabolic syndrome, diseases of the digestive tract and kidneys were less frequent. Cardiovascular risk (CVR) levels were high after the age of 50, gastrointestinal risk was less frequent. Fibrinolysis minor disorders were observed in patients with low comorbidity, namely fibrinolytic and proteolytic activity of blood as a part of high CVR progressively deteriorated and the level of fibrinogen and C-reactive protein increased in the patients at the age after 50 (especially 60) on the background of high comorbidity levels. Conclusions. The level of comorbidity and CVR increased in patients with OA with age, increase in disease severity and duration. These phenomena were accompanied by progressive disorders in fibrinolytic and proteolytic activity of the blood, increased levels of fibrinogen and C-reactive protein as one of the components of CVR.
Berstneva SV, Uryasyev OM, Dubinina II. Narushenie systemy fibrinoliza u bolnykh sakharnym diabetom v sochetanii s hipotireozom. Zemskiy vrach. 2015;1(25):49–53
Veremeenko NK. Proteoliz v norme i patologii. Kyiv: Zdorovia; 1993
Honcharuk LM, Fediv OI. Changes of intensity of plasma fibrinolysis and proteolysis and their correction by gastroduodenopathy, induced by NSAID's in patients with ostheoarthritis. Svir medytsyny ta biolohii. 2010;2:39–42
Kovalenko VM. Kalkuliator kardiovaskuliarnoho ryzyku. Zdorovia Ukrainy. 2010;3:6–8
Kovalenko VM. Komorbidnist i shliakhy funktsionalnoi farmakoterapii v revmatolohii. Ukraiinskyi revmatolohichnyi zhurnal. 2014;2(56):12–13
Kovalenko SV, Dorofeiev AE. Aktyvnist fibrynolitychnoi i proteolitychnoi system krovi u khvorykh na khronichne obstruktyvne zakhvoriuvannia lehen ta bronkhialnu astmu. Ukraiinskyi pulmonolohichnyi zhurnal. 2012;3:35–37
Mahalias VM, Mikheiev AO, Rohovyi IuIe, et al. Suchasni metodyky eksperymentalnykh i klinichnykh doslidzhen tsentralnoi naukovo-doslidnoi labaratorii Bukovynskoi derzhavnoi medychnoi akademii. Navch.-metod. posibnyk. Chernivtsi: 2001. 42 p.
Kovalenko VM, Shuba NM. Natsionalnyi pidruchnyk z revmatolohii. Kyiv: Morion; 2013. 672 p.
Fadieienko HD, Nesen AO. Komorbidnist ta intehratyvna rol terapii vnutrishnikh orhaniv. Ukraiinskyi terapevtychnyi zhurnal. 2015;2:7–15
Fadieienko HD, Hridniev OIe, Nesen AO, et al. Komorbidnist i vysokyi kardiovaskuliarnyi ryzyk – kliuchovi pytannia suchasnoi medytsyny. Ukraiinskyi terapevtychnyi zhurnal. 2013;1:102–107
Iuzvenko TIu. Fibrynolitychna aktyvnist krovi u khvorykh na tsukrovyi diabet 2-ho typu v poiednanni z hipotyreozom. Mizhnarodnyi endokrynolohichnyi zhurnal. 2015;3(67):39–42
Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classitying prognostic comorbidity in longitudinal studies: development and validation. J Chron Dis. 1987;40(50):373–383. DOI: http://doi.org/10.1016/0021-9681(87)90171-8
Marengoni A, Angleman S, Fratiglioni L. Prevalence of disability according to multimorbiditi and disease clustering: a population based – study. J Comorbidity. 2011;1(1):11–18. DOI: http://doi.org/10.15256/joc.2011.1.3
Safford MM, Allison JJ, Kiefe CI, Safford MM. Patient complexity: more than comorbidity, the vector model of complexity. J Gen Int Med. 2007;22(3):382–390. DOI: http://doi.org/10.1007/s11606-007-0307-0 [PMid: 18026806][PMCid: PMC2219701]
Uhlig K, Leff B, Kent D, et al. A framework for crafting clinical practice guidelines that are relevant to the care and management of people with comorbidity. J Gen Int Med. 2014;29(4):670–679
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.